English
中文简体
中文繁体
Company
Overview
Board of Directors
Partnering
Core competence
Technology
Bispecific
Proprietary ADC Platform
Mix-mAb
Publications
Pipeline
Overview
Envafolimab(KN035)
KN046
KN026
JSKN003
KN026+KN046
KN019
JSKN033
JSKN016
Investors
Information Disclosure
Corporate Governance
Stock Information
Corporate Communications
Email Subscription
News
Press Release
Media Report
Career
Corporate Culture
Job Opportunities
Contact Us
Company
Overview
Board of Directors
Partnering
Core competence
Technology
Bispecific
Proprietary ADC Platform
Mix-mAb
Publications
Pipeline
Overview
Envafolimab(KN035)
KN046
KN026
JSKN003
KN026+KN046
KN019
JSKN033
JSKN016
Investors
Information Disclosure
Corporate Governance
Stock Information
Corporate Communications
Email Subscription
News
Press Release
Media Report
Career
Corporate Culture
Job Opportunities
Contact Us
English
中文简体
中文繁体
Investors
Information Disclosure
Listing Documents
Financial Reports
Announcements & Circulars
Company Presentation
Corporate Governance
Stock Information
Corporate Communications
Email Subscription
Company Presentation
Alphamab Oncology（9966.HK）2023 Annual Results Presentation
2024-03-29
Alphamab Oncology（9966.HK）2023 Interim Results Presentation
2023-08-24
2022 Annual Results Presentation
2023-04-02
2022 Interim Result Investor Presentation
2022-09-01
Alphamab Oncology Investor Presentation
2022-03-29
Alphamab Oncology Investor Presentation
2021-12-29
Alphamab Oncology Investor Presentation
2021-08-30
Updated Company Presentation
2021-05-12
AACR poster #1660_Preliminary Safety, Tolerability and Efficacy Results of KN046 (an anti-PD-L1/CTLA-4 Bispecific Antibody) in combination with Nab-paclitaxel in Metastatic Triple-negative Breast Cancer (mTNBC)
2021-04-12
2020 Annual Result Investor Presentation
2021-03-24
WCLC 2020 Mini oral report-Preliminary safety, efficacy results of KN046 (bispecific anti-PD-L1/CTLA4) in subjects with rare thoracic tumors
2021-02-01
WCLC 2020 poster-A phase II study of KN046 (a bispecific anti-PDL1/CTLA-4) in patients (pts) with metastatic nonsmall cell lung cancer (NSCLC)
2021-02-01
Updated cooperate presentation
2021-01-21
ASCO-GI poster-The preliminary efficacy and safety of KN046 plus concurrent chemoradiation therapy in recurrent and metastatic esophageal squamous cell carcinoma
2021-01-18
2020 Jefferies Virtual London Healthcare Conference Presentation
2020-11-16
SITC poster - Preliminary Safety, Tolerability and Efficacy Results of KN026 in combination with KN046 in Patients with HER2 aberrated solid tumors
2020-11-12
27th Annual CITIC CLSA Flagship Investors' Forum Presentation
2020-09-08
2020 Interim Result Investor Presentation
2020-08-28
Company recent development report - July 2020
2020-07-30
AACR poster #1181 - Using translational tumor growth inhibition modeling approach and population PK analysis to predict efficacious doses for KN026, a HER2 bispecific antibody
2020-06-22
2020 Jefferies Virtual Healthcare Conference
2020-06-02
ASCO poster #3021 - Envafolimab (KN035) in advanced tumors with mismatch-repair deficiency
2020-05-29
ASCO poster #1041 - Preliminary Safety, Efficacy and Pharmacokinetics (PK) Results of KN026, a HER2-targeted Bispecific Antibody in Patients (pts) with HER2-positive Metastatic Breast Cancer
2020-05-29
ASCO poster #3020 - The preliminary efficacy and safety data of KN046 (bispecific anti-PD-L1/CTLA4) in patients failed on prior immune checkpoint inhibitors therapy
2020-05-29
Using translational tumor growth inhibition modeling approach and population PK analysis to predict efficacious doses for KN026, a HER2 bispecific antibody
2020-05-28
Envafolimab (KN035) in advanced tumors with mismatch-repair deficiency
2020-05-28
The preliminary efficacy and safety data of KN046 in patients failed on prior immune checkpoint inhibitors therapy
2020-05-17
Preliminary safety, efficacy and pharmacokinetics (PK) results of KN026, a HER2 bispecific antibody in patients (pts) with HER2-positive metastatic breast cancer
2020-05-17
